Related Experiment Video
Updated: Aug 5, 2026

04:21
A Minimally Invasive Method for Intratracheal Instillation of Drugs in Neonatal Rodents to Treat Lung Disease
Published on: August 4, 2021
MEK Inhibitor Associated Airway Injury in an Infant With Noonan Syndrome: A Case Report
Veronica Drozdowski-Nuccio1,2, Rachel D Yoon3, Steven Tomasi1
1Division of Pediatric Otolaryngology-Head and Neck Surgery, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
The Laryngoscope
|July 26, 2026
Summary
Trametinib, a MEK inhibitor, caused airway mucosal sloughing and scarring in an infant with Noonan syndrome. This highlights the potential for airway toxicity with MEK inhibitor therapies.
Area of Science:
- Pediatric Oncology
- Pharmacology
- Genetics
Background:
- Noonan syndrome is a genetic disorder associated with increased risk of certain cancers.
- MEK inhibitors, such as trametinib, are used in treating some conditions, including certain cancers.
- Airway complications are not commonly reported side effects of MEK inhibitors.